Selection and management of hepatitis C virus-infected patients for the kidney transplant waiting list

David Roth, Roy Bloom

Research output: Chapter in Book/Report/Conference proceedingChapter

11 Citations (Scopus)

Abstract

Hepatitis C virus (HCV) infection has been demonstrated to be present in a significant number of ESRD patients, and infection with this virus has been shown to have a detrimental impact on patient survival in both the dialysis and transplant patient populations. Studies have shown that 10-25% of pre-kidney transplant candidates have advanced liver injury with stage 3 or 4 disease (cirrhosis) when biopsied during the pretransplant evaluation. To identify those patients in whom a more extensive workup is required, all transplant candidates should be initially screened for anti-HCV antibody and/or active viremia using nucleic acid testing depending on the prevalence of HCV in the community. Although efforts have been directed at finding a reliable noninvasive marker of advanced liver disease in this patient population, liver biopsy remains the gold standard and should be obtained during the pretransplant evaluation in all patients determined to have active HCV infection. There is general agreement that patients with established or decompensated cirrhosis should be referred to the liver transplant team for consideration of combined liver-kidney transplantation. Patients on the kidney transplant waiting list should be monitored on a regular basis to identify those who might have progressive liver disease. This is especially relevant in an era when waiting times at some centers approach 5-7 years. There is no consensus on whether the pretransplant patient with active HCV viremia should be treated with antiviral agents prior to transplant. There is some largely anecdotal evidence that inducing a sustained virological response prior to transplant might lessen the risk of developing posttransplant diabetes and immune complex-mediated glomerular disease in the allograft. Whereas there is good evidence that the majority of patients achieving a sustained virological response prior to transplant do not relapse following the introduction of immunosuppression, there are limited data as to whether this has a positive impact on the progression of liver injury. Several studies have demonstrated that the use of interferon in the posttransplant setting is associated with an increased risk of allograft rejection; thus, any efforts to eradicate HCV should be focused on the pretransplant period. In summary, a thorough screening process to identify HCV infection in the pre-kidney transplant candidate, including the staging of liver disease in those determined to have viremia, is necessary so that the most appropriate treatment plan can be developed for each patient.

Original languageEnglish (US)
Title of host publicationHepatitis C in Renal Disease, Hemodialysis and Transplantation
PublisherS. Karger AG
Pages66-76
Number of pages11
Volume176
ISBN (Print)9783805598217, 9783805598200
DOIs
StatePublished - Jan 23 2012

Fingerprint

Waiting Lists
Hepacivirus
Transplants
Kidney
Virus Diseases
Viremia
Liver Diseases
Liver
Allografts
Fibrosis
Hepatitis C Antibodies
Wounds and Injuries
Antigen-Antibody Complex
Liver Transplantation
Kidney Transplantation
Immunosuppression
Nucleic Acids
Interferons
Population
Chronic Kidney Failure

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Roth, D., & Bloom, R. (2012). Selection and management of hepatitis C virus-infected patients for the kidney transplant waiting list. In Hepatitis C in Renal Disease, Hemodialysis and Transplantation (Vol. 176, pp. 66-76). S. Karger AG. https://doi.org/10.1159/000333774

Selection and management of hepatitis C virus-infected patients for the kidney transplant waiting list. / Roth, David; Bloom, Roy.

Hepatitis C in Renal Disease, Hemodialysis and Transplantation. Vol. 176 S. Karger AG, 2012. p. 66-76.

Research output: Chapter in Book/Report/Conference proceedingChapter

Roth, D & Bloom, R 2012, Selection and management of hepatitis C virus-infected patients for the kidney transplant waiting list. in Hepatitis C in Renal Disease, Hemodialysis and Transplantation. vol. 176, S. Karger AG, pp. 66-76. https://doi.org/10.1159/000333774
Roth D, Bloom R. Selection and management of hepatitis C virus-infected patients for the kidney transplant waiting list. In Hepatitis C in Renal Disease, Hemodialysis and Transplantation. Vol. 176. S. Karger AG. 2012. p. 66-76 https://doi.org/10.1159/000333774
Roth, David ; Bloom, Roy. / Selection and management of hepatitis C virus-infected patients for the kidney transplant waiting list. Hepatitis C in Renal Disease, Hemodialysis and Transplantation. Vol. 176 S. Karger AG, 2012. pp. 66-76
@inbook{38b3667bee7b45489e7ef7bedf4922df,
title = "Selection and management of hepatitis C virus-infected patients for the kidney transplant waiting list",
abstract = "Hepatitis C virus (HCV) infection has been demonstrated to be present in a significant number of ESRD patients, and infection with this virus has been shown to have a detrimental impact on patient survival in both the dialysis and transplant patient populations. Studies have shown that 10-25{\%} of pre-kidney transplant candidates have advanced liver injury with stage 3 or 4 disease (cirrhosis) when biopsied during the pretransplant evaluation. To identify those patients in whom a more extensive workup is required, all transplant candidates should be initially screened for anti-HCV antibody and/or active viremia using nucleic acid testing depending on the prevalence of HCV in the community. Although efforts have been directed at finding a reliable noninvasive marker of advanced liver disease in this patient population, liver biopsy remains the gold standard and should be obtained during the pretransplant evaluation in all patients determined to have active HCV infection. There is general agreement that patients with established or decompensated cirrhosis should be referred to the liver transplant team for consideration of combined liver-kidney transplantation. Patients on the kidney transplant waiting list should be monitored on a regular basis to identify those who might have progressive liver disease. This is especially relevant in an era when waiting times at some centers approach 5-7 years. There is no consensus on whether the pretransplant patient with active HCV viremia should be treated with antiviral agents prior to transplant. There is some largely anecdotal evidence that inducing a sustained virological response prior to transplant might lessen the risk of developing posttransplant diabetes and immune complex-mediated glomerular disease in the allograft. Whereas there is good evidence that the majority of patients achieving a sustained virological response prior to transplant do not relapse following the introduction of immunosuppression, there are limited data as to whether this has a positive impact on the progression of liver injury. Several studies have demonstrated that the use of interferon in the posttransplant setting is associated with an increased risk of allograft rejection; thus, any efforts to eradicate HCV should be focused on the pretransplant period. In summary, a thorough screening process to identify HCV infection in the pre-kidney transplant candidate, including the staging of liver disease in those determined to have viremia, is necessary so that the most appropriate treatment plan can be developed for each patient.",
author = "David Roth and Roy Bloom",
year = "2012",
month = "1",
day = "23",
doi = "10.1159/000333774",
language = "English (US)",
isbn = "9783805598217",
volume = "176",
pages = "66--76",
booktitle = "Hepatitis C in Renal Disease, Hemodialysis and Transplantation",
publisher = "S. Karger AG",

}

TY - CHAP

T1 - Selection and management of hepatitis C virus-infected patients for the kidney transplant waiting list

AU - Roth, David

AU - Bloom, Roy

PY - 2012/1/23

Y1 - 2012/1/23

N2 - Hepatitis C virus (HCV) infection has been demonstrated to be present in a significant number of ESRD patients, and infection with this virus has been shown to have a detrimental impact on patient survival in both the dialysis and transplant patient populations. Studies have shown that 10-25% of pre-kidney transplant candidates have advanced liver injury with stage 3 or 4 disease (cirrhosis) when biopsied during the pretransplant evaluation. To identify those patients in whom a more extensive workup is required, all transplant candidates should be initially screened for anti-HCV antibody and/or active viremia using nucleic acid testing depending on the prevalence of HCV in the community. Although efforts have been directed at finding a reliable noninvasive marker of advanced liver disease in this patient population, liver biopsy remains the gold standard and should be obtained during the pretransplant evaluation in all patients determined to have active HCV infection. There is general agreement that patients with established or decompensated cirrhosis should be referred to the liver transplant team for consideration of combined liver-kidney transplantation. Patients on the kidney transplant waiting list should be monitored on a regular basis to identify those who might have progressive liver disease. This is especially relevant in an era when waiting times at some centers approach 5-7 years. There is no consensus on whether the pretransplant patient with active HCV viremia should be treated with antiviral agents prior to transplant. There is some largely anecdotal evidence that inducing a sustained virological response prior to transplant might lessen the risk of developing posttransplant diabetes and immune complex-mediated glomerular disease in the allograft. Whereas there is good evidence that the majority of patients achieving a sustained virological response prior to transplant do not relapse following the introduction of immunosuppression, there are limited data as to whether this has a positive impact on the progression of liver injury. Several studies have demonstrated that the use of interferon in the posttransplant setting is associated with an increased risk of allograft rejection; thus, any efforts to eradicate HCV should be focused on the pretransplant period. In summary, a thorough screening process to identify HCV infection in the pre-kidney transplant candidate, including the staging of liver disease in those determined to have viremia, is necessary so that the most appropriate treatment plan can be developed for each patient.

AB - Hepatitis C virus (HCV) infection has been demonstrated to be present in a significant number of ESRD patients, and infection with this virus has been shown to have a detrimental impact on patient survival in both the dialysis and transplant patient populations. Studies have shown that 10-25% of pre-kidney transplant candidates have advanced liver injury with stage 3 or 4 disease (cirrhosis) when biopsied during the pretransplant evaluation. To identify those patients in whom a more extensive workup is required, all transplant candidates should be initially screened for anti-HCV antibody and/or active viremia using nucleic acid testing depending on the prevalence of HCV in the community. Although efforts have been directed at finding a reliable noninvasive marker of advanced liver disease in this patient population, liver biopsy remains the gold standard and should be obtained during the pretransplant evaluation in all patients determined to have active HCV infection. There is general agreement that patients with established or decompensated cirrhosis should be referred to the liver transplant team for consideration of combined liver-kidney transplantation. Patients on the kidney transplant waiting list should be monitored on a regular basis to identify those who might have progressive liver disease. This is especially relevant in an era when waiting times at some centers approach 5-7 years. There is no consensus on whether the pretransplant patient with active HCV viremia should be treated with antiviral agents prior to transplant. There is some largely anecdotal evidence that inducing a sustained virological response prior to transplant might lessen the risk of developing posttransplant diabetes and immune complex-mediated glomerular disease in the allograft. Whereas there is good evidence that the majority of patients achieving a sustained virological response prior to transplant do not relapse following the introduction of immunosuppression, there are limited data as to whether this has a positive impact on the progression of liver injury. Several studies have demonstrated that the use of interferon in the posttransplant setting is associated with an increased risk of allograft rejection; thus, any efforts to eradicate HCV should be focused on the pretransplant period. In summary, a thorough screening process to identify HCV infection in the pre-kidney transplant candidate, including the staging of liver disease in those determined to have viremia, is necessary so that the most appropriate treatment plan can be developed for each patient.

UR - http://www.scopus.com/inward/record.url?scp=84879845126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879845126&partnerID=8YFLogxK

U2 - 10.1159/000333774

DO - 10.1159/000333774

M3 - Chapter

SN - 9783805598217

SN - 9783805598200

VL - 176

SP - 66

EP - 76

BT - Hepatitis C in Renal Disease, Hemodialysis and Transplantation

PB - S. Karger AG

ER -